Pulmonary fibrosis is a progressive disease characterized by lung remodeling due to excessive deposition of extracellular matrix. In this study, the
bleomycin experimental model of
pulmonary fibrosis was employed to investigate the anti-fibrotic and immunomodulatory activity of the inhibition of MALT1
protease activity. Mice received a single intra-tracheal administration of
bleomycin (1 mg/kg) in the presence or absence of MI-2, a selective MALT1 inhibitor, (a dose of 30 mg/kg administered intra-peritoneally 1 h after
bleomycin and daily until the end of the experiment). Seven days after
bleomycin instillation mice were sacrificed and bronchoalveolar lavage fluid analysis, measurement of
collagen content in the lung, histology, molecular analysis and immunohistochemistry were performed. To evaluate mortality and
body weight gain a subset of mice was administered daily with MI-2 for 21 days. Mice that received MI-2 showed decreased
weight loss and mortality, inflammatory cells infiltration,
cytokines overexpression and tissue injury. Moreover, biochemical and immunohistochemical analysis displayed that MI-2 was able to modulate the excessive production of
reactive oxygen species and the inflammatory mediator upregulation induced by
bleomycin instillation. Additionally, MI-2 demonstrated anti-fibrotic activity by reducing
transforming growth factor-β (TGF-β), α-smooth muscle actin (α-SMA) and receptor associated factor 6 (
TRAF6) expression. The underlying mechanisms for the protective effect of MI-2
bleomycin induced
pulmonary fibrosis may be attributed to its inhibition on NF-κB pathway. This is the first report showing the therapeutic role of MALT1 inhibition in a
bleomycin model of
pulmonary fibrosis, thus supporting further preclinical and clinical studies.